ArticleJournal of pharmaceutical policy and practice2026
Economic implications of the different statin prescribing patterns in Central Portugal: a longitudinal analysis.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Statins are one of the most widely used therapeutic classes and have significantly contributed to health care expenditures with reported variability between countries and regions. We aim to identify the economic implications of different statin prescription patterns in the central region of Portugal. Methods: A retrospective longitudinal study of statin consumption between 2010 and 2022 in the central region, with data obtained from the national administrative claim database. Prescription and expenditure (retail price) were analysed at the municipality level. A score was created for the quartile position (1 = first to 4 = fourth) of each municipality in the distributions of consumption and expenditure for each year. An overall score was created for the study period by aggregating yearly scores. A four-quadrant analysis with the overall scores of cost/DDD and DDD/1000inhabitants/day (DID) was conducted. Bivariate and multivariate analyses were performed. Results: Statin consumption increased from 64 DDD/1000inhabitants/day (DID) to 149 DID, while cost/DDD and cost/inhabitant decreased from 0.77 € to 0.26 € and from 17.84 € to 13.99 €, respectively. Prescription pattern of high-intensity statins increased from 26% to 74% of the DDD consumed. A four-quadrant plot revealed discrepancies between the municipalities. These discrepancies were associated with the percentage of pitavastatin in DDD (F = 4.604; Conclusion: Differences in prescribing patterns resulted in very different proportions of patients treated and expenses associated with the consumption of these lipid-lowering agents. Further analysis should be carried out to understand the financial implications of prescribing new (patent-protected) medicines in Portugal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.